Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up - PubMed (original) (raw)

Clinical Trial

Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up

J Estape et al. Ann Surg. 1991 Mar.

Abstract

Seventy consecutive patients were entered in a two-arm randomized trial after surgical resection for locally advanced gastric cancer. In the first arm, 37 patients were included as a control group, receiving no further treatment after surgery. In the second arm, 33 patients were treated with adjuvant chemotherapy consisting of mitomycin C (MMC), 20 mg/m2 administered intravenously once every 6 weeks for four consecutive cycles. All patients in both arms were followed in the same way for 5 years. At 5 years 23 of 37 patients in the control arm and 7 of 33 patients in the treatment arm were dead because of relapse. Actuarial survival curve was statistically significant in favor of patients given adjuvant MMC (p less than 0.001). After 10 years follow-up, 31 of 37 patients in the control arm and 16 out of 33 patients in the treatment arm were dead because of relapse, the statistical differences continuing in the actuarial survival curve in favor of treated patients (p less than 0.01). The best advantages of adjuvant treatment were observed in the T3N0M0 stage. The most frequent relapse site was the peritoneal cavity and the relapse pattern shows special decrease in liver metastases in treated patients. Toxicity was acute and mild. No delayed toxicity or second malignancies were observed. These data suggest that adjuvant MMC after resected surgery of gastric cancer is a successful treatment and its effects are still evident after 10 years of follow-up.

PubMed Disclaimer

Cited by

Outcome of surgical treatment for patients with locoregional recurrence of gastric cancer.
Nunobe S, Hiki N, Ohyama S, Aikou S, Sano T, Yamaguchi T. Nunobe S, et al. Langenbecks Arch Surg. 2011 Feb;396(2):161-6. doi: 10.1007/s00423-010-0730-2. Epub 2010 Dec 14. Langenbecks Arch Surg. 2011. PMID: 21153661
Post-operative radiochemotherapy in patients with gastric cancer: one department's experience of 56 patients.
Spych M, Serbiak B, Rychter A, Jesien-Lewandowicz E, Gottwald L, Fijuth J. Spych M, et al. Br J Radiol. 2011 May;84(1001):457-63. doi: 10.1259/bjr/25406515. Epub 2011 Feb 8. Br J Radiol. 2011. PMID: 21304007 Free PMC article.
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
Neri B, de Leonardis V, Romano S, Andreoli F, Pernice LM, Bruno L, Borrelli D, Valeri A, Fabbroni S, Intini C, Cini G. Neri B, et al. Br J Cancer. 1996 Feb;73(4):549-52. doi: 10.1038/bjc.1996.95. Br J Cancer. 1996. PMID: 8595173 Free PMC article. Clinical Trial.
Adjuvant therapy in resectable gastric cancer.
Bleiberg H, Gerard B, Deguiral P. Bleiberg H, et al. Br J Cancer. 1992 Dec;66(6):987-91. doi: 10.1038/bjc.1992.399. Br J Cancer. 1992. PMID: 1457367 Free PMC article. Review. No abstract available.
Neoadjuvant therapy.
Niederhuber JE. Niederhuber JE. Ann Surg. 1999 Mar;229(3):309-12. doi: 10.1097/00000658-199903000-00002. Ann Surg. 1999. PMID: 10077041 Free PMC article. No abstract available.

References

1. Gan To Kagaku Ryoho. 1987 Apr;14(4):1136-42 - PubMed
1. Biometrics. 1973 Sep;29(3):579-84 - PubMed
1. Semin Oncol. 1985 Sep;12(3 Suppl 4):57-62 - PubMed
1. Cancer Res. 1985 Dec;45(12 Pt 1):6523-37 - PubMed
1. Cancer Immunol Immunother. 1986;22(2):148-54 - PubMed

Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up - PubMed (original) (raw)